Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Targeted therapy improves survival in lung cancer patients
September 2, 2015
The world’s largest clinical trial comparing two targeted therapies for advanced squamous cell carcinoma of the lung has found that a newer therapy called afatinib decreased the risk of cancer progression and the risk of death by 19% compared to an older therapy called erlotinib.
The clinical trial, co-led by Dr. Glen Goss, involved nearly 800 patients in 23 countries whose cancer had stopped responding to platinum-based therapies (the first-line treatment).
Afatinib and erlotinib both inhibit the epidermal growth factor receptor (EGFR) which is responsible for growth and proliferation of cancer cells. However afatinib also inhibits related receptors in the Erb family, and does so in an irreversible manner.
A number of patients at The Ottawa Hospital participated in the trial, and many more are now poised to benefit from this therapy. The results were published in
Lancet Oncology
.
Co-authors
: Jean-Charles Soria, Enriqueta Felip, Manuel Cobo Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, LUX-Lung 8 Investigators.
Funders
: Boehringer Ingelheim
About The Ottawa Hospital
The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.
For further information, please contact
Jennifer Ganton
Director, Communications and Public Relations,
Ottawa Hospital Research Institute
Office: 613-798-5555 x 73325
Cell:613-614-5253
jganton@ohri.ca